Alpha-1 Biologics Overview

  • Founded
  • 2011

Founded
  • Status
  • Private

  • Latest Deal Type
  • Angel

  • (Cancelled)
  • Latest Deal Amount
  • $200K

  • Investors
  • 2

Alpha-1 Biologics General Information

Description

Developer of a biotechnology designed to develop drugs and diagnostic tests. The company's biotechnology provide several critical functions including protection of discoveries, translation of discoveries and preparation of statistical analyses and reports to support safety and efficacy, enabling researchers to regulate cholesterol levels transported by immune cells.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Drug Discovery
Primary Office
  • 25 Health Sciences Drive
  • Suite 110
  • NY 11790
  • United States
+1 (631) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alpha-1 Biologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Angel (individual) $200K Cancelled Startup
2. Angel (individual) 00.00 00.00 Completed Startup
1. Accelerator/Incubator Completed Startup
To view Alpha-1 Biologics’s complete valuation and funding history, request access »

Alpha-1 Biologics Patents

Alpha-1 Biologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3050962-A1 Therapeutic use of levorotatory beta-lactams in hematopoiesis, immuno-oncology therapy, and regulation of lipoprotein and apolipoprotein levels Pending 18-Jan-2017 000000000
US-20200016128-A1 Therapeutic use of levorotatory b-lactams in hematopoiesis, immuno-oncology therapy, and regulation of lipoprotein and apolipoprotein levels Granted 18-Jan-2017 000000000
US-20200383955-A1 Therapeutic use of tromethamine salt of l-ampicillin in hematopoiesis, immuno-oncology therapy, and regulation of lipoprotein and apolipoprotein levels Granted 18-Jan-2017 000000000
US-10709693-B2 Therapeutic use of tromethamine salt of l-ampicilline in hematopoiesis, immuno-oncology therapy, and regulation of lipoprotein and apolipoprotein levels Active 18-Jan-2017 000000000 0
US-10413530-B2 Pharmaceutical composition containing the tromethamine salt of l-ampicillin Active 18-Jan-2017 A61K31/43 0
To view Alpha-1 Biologics’s complete patent history, request access »

Alpha-1 Biologics Executive Team (2)

Name Title Board Seat Contact Info
Cynthia Bristow Ph.D Founder, Chief Executive Officer, Chief Scientific Officer & Board Member
You’re viewing 1 of 2 executive team members. Get the full list »

Alpha-1 Biologics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Long Island High Technology Incubator Accelerator/Incubator 000 0000 000000 0
Ronald Winston Angel (individual) Minority 000 0000 000000 0
To view Alpha-1 Biologics’s complete investors history, request access »